Public Health Implications of Smokeless Tobacco Use as a Harm Reduction Strategy
David A. Savitz, PhD,
Roger E. Meyer, MD,
Jason M. Tanzer, PhD, DHC,
Sidney S. Mirvish, PhD and
Freddi Lewin, MD
At the time of the study, David A. Savitz was with the Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill. Roger E. Meyer is with the Department of Psychiatry, Georgetown University School of Medicine, Washington, DC, and the Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia. Jason M. Tanzer is with the Department of Oral Diagnosis, School of Dental Medicine, and the Department of Laboratory Medicine, School of Medicine, University of Connecticut Health Center, Farmington. Sidney S. Mirvish is with the Eppley Institute for Research in Cancer, University of Nebraska Medical Center, Omaha. Freddi Lewin is with the Department of Oncology, Karolinska Institute, Stockholm, Sweden.
Correspondence: Requests for reprints should be sent to David A. Savitz, PhD, Department of Community and Preventive Medicine, Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1057, New York, NY 10029 (e-mail: david.savitz{at}mssm.edu).
Harm reduction strategies involve promoting a product that hasadverse health consequences as a substitute for one that hasmore severe adverse health consequences. Smokeless tobacco lowin nitrosamine content offers potential benefits in reducingsmoking prevalence rates. Possible harm arises from the potentialfor such products to serve as a gateway to more harmful tobaccoproducts, public misinterpretation of "less harmful" as "safe,"distraction from the public health goal of tobacco elimination,and ethical issues involved in advising those marketing theseharmful products. We offer a research agenda to provide a strongerbasis for evaluating the risks and benefits of smokeless tobaccoas a means of reducing the adverse health effects of tobacco.
This article has been cited by other articles:
L. Biener and K. Bogen Receptivity to Taboka and Camel Snus in a U.S. test market
Nicotine Tob Res,
October 1, 2009;
11(10):
1154 - 1159.
[Abstract][Full Text][PDF]
M. Zeller, D. Hatsukami, and and the Strategic Dialogue on Tobacco Harm Reducti The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US
Tob. Control,
August 1, 2009;
18(4):
324 - 332.
[Abstract][Full Text][PDF]
D. S. Timberlake, J. Huh, and C. M. Lakon Use of propensity score matching in evaluating smokeless tobacco as a gateway to smoking
Nicotine Tob Res,
April 1, 2009;
11(4):
455 - 462.
[Abstract][Full Text][PDF]
N. Wiium, L. E. Aaro, and J. Hetland Subjective attractiveness and perceived trendiness in smoking and snus use: a study among young Norwegians
Health Educ. Res.,
February 1, 2009;
24(1):
162 - 172.
[Abstract][Full Text][PDF]
S Overland, J Hetland, and L E Aaro Relative harm of snus and cigarettes: what do Norwegian adolescents say?
Tob. Control,
December 1, 2008;
17(6):
422 - 425.
[Abstract][Full Text][PDF]
S S Hecht, S G Carmella, A Edmonds, S E Murphy, I Stepanov, X Luo, and D K Hatsukami Exposure to nicotine and a tobacco-specific carcinogen increase with duration of use of smokeless tobacco
Tob. Control,
April 1, 2008;
17(2):
128 - 131.
[Abstract][Full Text][PDF]
S. S. Hecht, S. G. Carmella, S. E. Murphy, W. T. Riley, C. Le, X. Luo, M. Mooney, and D. K. Hatsukami Similar Exposure to a Tobacco-Specific Carcinogen in Smokeless Tobacco Users and Cigarette Smokers
Cancer Epidemiol. Biomarkers Prev.,
August 1, 2007;
16(8):
1567 - 1572.
[Abstract][Full Text][PDF]